Brief Summary

Compassionate Use requests will be considered for individuals who test positive for SARS-CoV-2 and where there is reasonable basis to believe that the patient is infected with a susceptible variant.

Detailed Description

Compassionate Use requests are only being considered in response to Individual Patient
Investigational New Drug (IND) applications.

Status
Available
EA Type
Individual Patients
Conditions
COVID-19
Interventions

Drug: REGN10933+REGN10987 combination therapy

Administered intravenously (IV) single dose
Other Name: Array

Contacts

Requests for compassionate use must be initiated by a treating physician. Physicians should contact
844-734-6643
compassionateuserequests@regeneron.com

Sponsors / Collaborators
Regeneron Pharmaceuticals
NCT Number
NCT04617535
Keywords
Post-exposure
MeSH Terms
COVID-19
Casirivimab and imdevimab drug combination